New PET tracer aims to reveal hidden Hormone-Making tumors

NCT ID NCT06246357

Recruiting now Diagnosis Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 4 times

Summary

This phase 2 study tests a radioactive tracer called [68Ga]Ga-PentixaFor to see if it can better identify adrenal tumors that produce excess hormones like aldosterone or cortisol. About 80 adults with known adrenal tumors and high hormone levels will receive the tracer before a PET scan. The goal is to improve diagnosis of functional adrenal tumors, which could guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [68Ga]Ga-PentixaFor (a radioactive tracer)
What this could lead to: If successful, this tracer could make it easier to identify which adrenal tumors are producing excess hormones, helping doctors choose the right treatment.
What could go wrong: This is an early phase 2 study with only 80 participants, so results may not apply to everyone. The tracer is still experimental and its accuracy needs further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUSHING'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoma Cushing syndrome hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUSHING'S SYNDROME HYPERALDOSTERONISM HYPERCORTISOLISM

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.